A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

October 31, 2026

Conditions
Venous Thromboembolism
Interventions
DRUG

SRSD107

SRSD107 is an investigational siRNA product for anticoagulants.

DRUG

enoxaparin

Enoxaparin is a low molecular weight heparin \[LMWH\] indicated for Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness.

All Listed Sponsors
lead

Sirius Therapeutics Co., Ltd.

INDUSTRY